Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

Tien Hoang, Toby C. Campbell, Chong Zhang, KyungMann Kim, Jill Kolesar, Kurt R. Oettel, Jules H. Blank, Emily Robinson, Harish G. Ahuja, Ron J. Kirschling, Peter H. Johnson, Michael S. Huie, Mary E. Wims, Martha Larson, Hilary R. Hernan, Anne M. TraynorInvestigational 2013 · DOI

BibTeX
@inproceedings{hoang2013vorinostat,
  author = {Tien Hoang and Toby C. Campbell and Chong Zhang and KyungMann Kim and Jill Kolesar and Kurt R. Oettel and Jules H. Blank and Emily Robinson and Harish G. Ahuja and Ron J. Kirschling and Peter H. Johnson and Michael S. Huie and Mary E. Wims and Martha Larson and Hilary R. Hernan and Anne M. Traynor},
  title = {{Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study}},
  booktitle = {Investigational},
  year = {2013},
  doi = {10.1007/s10637-013-9980-5},
}

Loading related content...

Figure